Servier

GeNeuro is a clinical-stage biotechnology company based in Plan-Les-Ouates, Switzerland, specializing in the development of therapeutic drugs for diseases linked to the expression of pathogenic proteins derived from human endogenous retroviruses. The company primarily targets nervous system disorders, including multiple sclerosis and schizophrenia. Its lead product, GNbAC1, is a therapeutic monoclonal antibody aimed at treating multiple sclerosis, while temelimab, another candidate, neutralizes a pathogenic protein associated with the HERV-W family. In addition to its therapeutic developments, GeNeuro also focuses on creating diagnostic tests to measure multiple sclerosis-associated retrovirus-ENV proteins in patients. Founded in 2006, GeNeuro is committed to addressing the underlying causes of neurodegenerative and autoimmune diseases.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering and developing innovative treatments for cancer and rare genetic disorders related to cellular metabolism. The company specializes in small-molecule medicines targeting metabolic pathways, particularly in the context of hematologic malignancies, solid tumors, and genetic diseases. Agios offers TIBSOVO, an oral inhibitor for relapsed or refractory acute myeloid leukemia (AML), and IDHIFA, which targets AML patients with specific genetic mutations. Both drugs are undergoing various stages of clinical trials for broader applications, including frontline AML and cholangiocarcinoma. The company is also advancing other therapeutic candidates, such as mitapivat for pyruvate kinase deficiency, vorasidenib for solid tumors, and AG-270 for specific cancer types. Agios Pharmaceuticals employs a precision medicine approach to its research, aiming to identify genetically defined patient populations to enhance the efficacy of its treatments.

Symphogen is a biotechnology company focused on the development of recombinant polyclonal antibodies (rpAb), a novel class of biopharmaceuticals aimed at treating and preventing serious human diseases, including infectious diseases and cancer. The company specializes in creating these antibodies to address specific medical conditions, such as idiopathic thrombocytopenic purpura and the prevention of hemolytic disease in newborns, which can arise from adverse reactions to smallpox vaccinations. By providing targeted treatments, Symphogen enhances the ability of cancer patients to initiate therapy more promptly, thereby increasing the chances of successful outcomes in their treatment.